Davis, Scott <br/><br/>
Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.  [electronic resource] 

 -  Transplantation  04 2020 
 - 881-887 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1534-6080 
<br/><br/><label>Standard No.: </label>10.1097/TP.0000000000002913  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Biomarkers--blood<br/>Calcineurin Inhibitors--adverse effects<br/>Drug Monitoring<br/>Female<br/>Graft Rejection--diagnosis<br/>Graft Survival--drug effects<br/>HLA Antigens--immunology<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Isoantibodies--blood<br/>Kidney Transplantation--adverse effects<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Tacrolimus--adverse effects<br/>Time Factors<br/>Treatment Outcome